Mario Bitar, Roseanne Ferreira, Sagi Shprits, Omar Buksh, Naeem Bhojani, Bilal Chughtai, Kevin C. Zorn, Dean Elterman
Objective To present large‐scale safety outcomes, with a particular focus on postoperative bleeding following Aquablation for benign prostatic hyperplasia. Patients and Methods Patients who underwent Aquablation between 2019 and 2024 across Asia, Europe, and North America were assessed to evaluate trends in treated prostate sizes, which were visualised using density plots. A corporate prospective database was maintained, incorporating case recordings and data collected by on‐site company representatives. In addition, the incidence of postoperative bleeding—defined as transfusion or surgical takeback for haemostatic fulguration—was analysed using data from the United States Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database and procedure counts by the manufacturer. Results A total of 70 270 Aquablation procedures were evaluated over the period from 2019 to 2024. The mean (standard deviation) prostate volume was 87.3 (42.4) mL, with a maximum recorded size of 1189 mL. Density plot analysis of prostate volumes demonstrated consistent utilisation of Aquablation across the full range of prostate sizes throughout all years studied. The overall rate of blood transfusion or return to the operating room for haemostatic fulguration was 0.2%, indicating a favourable safety profile across a very wide range of prostate sizes. Conclusions Aquablation has been consistently utilised across a broad spectrum of prostate sizes, with a low overall rate of transfusion or return to the operating room for bleeding control. These findings highlight the procedure's broad applicability and favourable safety profile in real‐world practice from 2019 to 2024.
{"title":"Aquablation for benign prostatic hyperplasia: real‐world prostate size relevance and bleeding events across 6 years","authors":"Mario Bitar, Roseanne Ferreira, Sagi Shprits, Omar Buksh, Naeem Bhojani, Bilal Chughtai, Kevin C. Zorn, Dean Elterman","doi":"10.1111/bju.70118","DOIUrl":"https://doi.org/10.1111/bju.70118","url":null,"abstract":"Objective To present large‐scale safety outcomes, with a particular focus on postoperative bleeding following Aquablation for benign prostatic hyperplasia. Patients and Methods Patients who underwent Aquablation between 2019 and 2024 across Asia, Europe, and North America were assessed to evaluate trends in treated prostate sizes, which were visualised using density plots. A corporate prospective database was maintained, incorporating case recordings and data collected by on‐site company representatives. In addition, the incidence of postoperative bleeding—defined as transfusion or surgical takeback for haemostatic fulguration—was analysed using data from the United States Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database and procedure counts by the manufacturer. Results A total of 70 270 Aquablation procedures were evaluated over the period from 2019 to 2024. The mean (standard deviation) prostate volume was 87.3 (42.4) mL, with a maximum recorded size of 1189 mL. Density plot analysis of prostate volumes demonstrated consistent utilisation of Aquablation across the full range of prostate sizes throughout all years studied. The overall rate of blood transfusion or return to the operating room for haemostatic fulguration was 0.2%, indicating a favourable safety profile across a very wide range of prostate sizes. Conclusions Aquablation has been consistently utilised across a broad spectrum of prostate sizes, with a low overall rate of transfusion or return to the operating room for bleeding control. These findings highlight the procedure's broad applicability and favourable safety profile in real‐world practice from 2019 to 2024.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"2 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145759788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abderrahim-Oussama Batouche,Eugen Czeizler,Timo-Pekka Lehto,Andrew Erickson,Tolou Shadbahr,Teemu D Laajala,Joona Pohjonen,Tuomas Mirtti,Antti S Rannikko
OBJECTIVETo determine the likelihood of definitive treatment and risk of post-treatment recurrence for patients with Gleason Grade Group (GG) 2 cancer diagnosed using targeted biopsies relative to men with GG1 cancer diagnosed using systematic biopsies.MATERIALS AND METHODSWe performed a retrospective study using a large tertiary centre registry (the HUS Acamedic data lake) to retrieve data on prostate cancer (PCa) diagnosis, treatment, and cancer recurrence. We included patients with either GG1 PCa detected by systematic biopsies (n = 3317) or GG2 PCa detected with targeted biopsies (n = 554) between 1993 and 2019. We assessed the risk of curative treatment and recurrence after treatment. Kaplan-Meier curves were used to estimate treatment- and recurrence-free survival, and Cox proportional hazards regression was used to evaluate the risk of post-treatment recurrence.RESULTSPatients with systematic biopsy-detected GG1 cancer had a significantly longer median time to treatment (31 months) than those with targeted biopsy-detected GG2 cancer (4 months; P < 0.0001). Risk of recurrence after curative treatment was similar in the two groups, with the upper bound of the 95% confidence interval (CI) excluding any significant difference (hazard ratio 1.04, 95% CI 0.75-1.43; P = 0.83).CONCLUSIONMen diagnosed with GG2 PCa based on MRI-targeted biopsy had a similar risk of recurrence after treatment compared to men with GG1 disease diagnosed using systematic biopsy, although they were more likely to undergo curative treatment. These findings suggest that at least a portion of the apparent increase in GG2 diagnoses in the MRI era may reflect reclassification rather than more aggressive disease. Improved risk stratification is needed to identify which men with MRI-era GG2 cancer may be suitable for active surveillance.
目的：相对于采用系统活检诊断为GG1癌的男性，采用靶向活检诊断为Gleason Grade Group (GG) 2癌的患者确定治疗的可能性和治疗后复发的风险。材料和方法我们使用一个大型三级中心登记处（HUS学术数据湖）进行了一项回顾性研究，以检索前列腺癌（PCa）的诊断、治疗和癌症复发的数据。我们纳入了1993年至2019年间通过系统活检检测到GG1型前列腺癌（n = 3317）或通过靶向活检检测到GG2型前列腺癌（n = 554）的患者。我们评估了治愈治疗和治疗后复发的风险。Kaplan-Meier曲线用于估计无治疗和无复发生存期，Cox比例风险回归用于评估治疗后复发风险。结果系统活检检测到GG1癌患者的中位治疗时间（31个月）明显长于靶向活检检测到GG2癌患者（4个月，P < 0.0001）。两组治愈后复发的风险相似，95%置信区间（CI）上界排除任何显著差异（风险比1.04,95% CI 0.75-1.43; P = 0.83）。结论与系统活检诊断为GG1的男性相比，基于mri靶向活检诊断为GG2的男性治疗后复发的风险相似，尽管他们更有可能接受根治性治疗。这些发现表明，在MRI时代GG2诊断的明显增加中，至少有一部分可能反映了重新分类，而不是更具侵袭性的疾病。需要改进风险分层，以确定哪些患有mri时代GG2癌的男性可能适合进行主动监测。
{"title":"Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer.","authors":"Abderrahim-Oussama Batouche,Eugen Czeizler,Timo-Pekka Lehto,Andrew Erickson,Tolou Shadbahr,Teemu D Laajala,Joona Pohjonen,Tuomas Mirtti,Antti S Rannikko","doi":"10.1111/bju.70109","DOIUrl":"https://doi.org/10.1111/bju.70109","url":null,"abstract":"OBJECTIVETo determine the likelihood of definitive treatment and risk of post-treatment recurrence for patients with Gleason Grade Group (GG) 2 cancer diagnosed using targeted biopsies relative to men with GG1 cancer diagnosed using systematic biopsies.MATERIALS AND METHODSWe performed a retrospective study using a large tertiary centre registry (the HUS Acamedic data lake) to retrieve data on prostate cancer (PCa) diagnosis, treatment, and cancer recurrence. We included patients with either GG1 PCa detected by systematic biopsies (n = 3317) or GG2 PCa detected with targeted biopsies (n = 554) between 1993 and 2019. We assessed the risk of curative treatment and recurrence after treatment. Kaplan-Meier curves were used to estimate treatment- and recurrence-free survival, and Cox proportional hazards regression was used to evaluate the risk of post-treatment recurrence.RESULTSPatients with systematic biopsy-detected GG1 cancer had a significantly longer median time to treatment (31 months) than those with targeted biopsy-detected GG2 cancer (4 months; P < 0.0001). Risk of recurrence after curative treatment was similar in the two groups, with the upper bound of the 95% confidence interval (CI) excluding any significant difference (hazard ratio 1.04, 95% CI 0.75-1.43; P = 0.83).CONCLUSIONMen diagnosed with GG2 PCa based on MRI-targeted biopsy had a similar risk of recurrence after treatment compared to men with GG1 disease diagnosed using systematic biopsy, although they were more likely to undergo curative treatment. These findings suggest that at least a portion of the apparent increase in GG2 diagnoses in the MRI era may reflect reclassification rather than more aggressive disease. Improved risk stratification is needed to identify which men with MRI-era GG2 cancer may be suitable for active surveillance.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"14 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on 'Male sex is a risk factor for detrusor pressure jeopardising the upper urinary tract after spinal cord injury'.","authors":"Longtu Ma,Rui Lu,Zhilong Dong","doi":"10.1111/bju.70107","DOIUrl":"https://doi.org/10.1111/bju.70107","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"57 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Matthias May,Anton Kravchuk,Ralph M Wirtz,Thorsten H Ecke,Axel Heidenreich
{"title":"Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts.","authors":"Matthias May,Anton Kravchuk,Ralph M Wirtz,Thorsten H Ecke,Axel Heidenreich","doi":"10.1111/bju.70113","DOIUrl":"https://doi.org/10.1111/bju.70113","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"170 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response to: ‘Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts’","authors":"José Rubio‐Briones","doi":"10.1111/bju.70114","DOIUrl":"https://doi.org/10.1111/bju.70114","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"6 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145731055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Collene E. Anderson, Veronika Birkhäuser, Martin W. G. Brinkhof, Thomas M. Kessler
{"title":"RE: Comment: ‘Male sex is a risk factor for detrusor pressure jeopardising the upper urinary tract in patients with spinal cord injury’","authors":"Collene E. Anderson, Veronika Birkhäuser, Martin W. G. Brinkhof, Thomas M. Kessler","doi":"10.1111/bju.70106","DOIUrl":"https://doi.org/10.1111/bju.70106","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"98 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145711403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>Like most journals, BJUI relies on the hard work and dedication of its peer reviewers and we are grateful to them all. Each month the Editorial Team nominates peer reviewers whose reviews have stood out for their quality and timeliness and those selected as the best are highlighted on this page in recognition of their exceptional work.</p><p> <b>Tanja Hüsch</b> </p><p>Her academic focus lies in functional and reconstructive urology, with expertise in neurourology, pelvic floor dysfunction, and urinary incontinence. She has led and contributed to several clinical studies on continence surgery and diagnostic innovation and received several honorary positions at national and international levels.</p><p>Dr. Hüsch's research has been supported by competitive scientific grants and acknowledged with national awards for applied clinical research. She has authored more than 70 peer-reviewed publications and contributed multiple textbook chapters to leading urology references.</p><p>As a Fellow of the European Board of Urology (FEBU), Dr. Tanja Hüsch serves as examiner and mentor, actively promoting academic advancement, education, and gender equity in urology.</p><p> <b>Rustom Manecksha</b> </p><p>He is a consultant urological surgeon with special interests in kidney stone disease and BPH and Clinical Associate Professor of surgery at Trinity College, Dublin. Prof. Manecksha is an active HST trainer and a former National Training Programme Director for Urology. He has an active research and academic profile with over 100 peer-reviewed publications.</p><p> <b>Luis Ribeiro</b> </p><p> <b>Jill Wruble</b> </p><p>Dr Wruble earned her undergraduate degree from Williams College and her medical degree from the New York Institute of Technology College of Osteopathic Medicine. She served in the United States Army Medical Corps, including a tour as a general medical officer at the 43rd MASH in Camp Humphreys, South Korea. She completed her internship and diagnostic radiology residency at Walter Reed Army Medical Center in Washington, D.C., followed by post-doctoral fellowships in body imaging at Georgetown University Medical School and Johns Hopkins Hospital in Baltimore. Dr Wruble retired from the Army with the rank of major. She was the recipient of an honorary doctorate and presented the medical school commencement address at the New York Institute of technology in 2025.</p><p>Dr Wruble serves on the National Cancer Institute's Board for Cancer Screening and Prevention, which critically evaluates medical literature and maintains evidence-based, up-to-date summaries on cancer screening and prevention for healthcare professionals and patients.</p><p>Dr Wruble has worked to enrich radiology teaching in underserved countries. She has contributed substantial time teaching and mentoring residents at Kilimanjaro Christian Medical Center in Moshi, Tanzania. She has also dev
像大多数期刊一样，《北京科技大学学报》依靠同行审稿人的辛勤工作和奉献精神，我们感谢他们所有人。每个月，编辑团队都会提名评审质量和及时性突出的同行审稿人，那些被评为最佳的审稿人将在本页突出显示，以表彰他们的杰出工作。Tanja h sch，主要研究方向为功能和重建泌尿外科，擅长神经病学、盆底功能障碍和尿失禁。她领导并参与了几项关于失禁手术和诊断创新的临床研究，并在国家和国际层面获得了多个荣誉职位。他的研究得到了竞争性科学基金的支持，并获得了国家应用临床研究奖。她撰写了70多篇同行评审的出版物，并为领先的泌尿学参考文献贡献了多个教科书章节。作为欧洲泌尿外科委员会（FEBU）的成员，Tanja h博士作为审查员和导师，积极推动泌尿外科的学术进步、教育和性别平等。Rustom Manecksha他是一名泌尿外科顾问医生，对肾结石疾病和BPH有特殊兴趣，都柏林三一学院临床外科副教授。Manecksha教授是一名活跃的HST培训师和前泌尿外科国家培训项目主任。他拥有活跃的研究和学术形象，发表了100多篇同行评审的出版物。luisribeiro Jill Wruble博士在威廉姆斯学院获得本科学位，并在纽约理工学院骨科医学院获得医学学位。她曾在美国陆军医疗团服役，包括在韩国汉弗莱斯军营的第43医疗团担任一般医疗官。她在华盛顿特区的沃尔特里德陆军医疗中心完成了她的实习和诊断放射学住院医师，随后在乔治城大学医学院和巴尔的摩的约翰霍普金斯医院获得了身体成像博士后奖学金。鲁布尔博士以少校军衔从陆军退役。她获得了荣誉博士学位，并于2025年在纽约理工学院医学院毕业典礼上发表了演讲。Wruble博士在国家癌症研究所癌症筛查和预防委员会任职，该委员会对医学文献进行严格评估，并为医疗保健专业人员和患者维护以证据为基础的最新癌症筛查和预防摘要。Wruble博士致力于丰富服务不足国家的放射学教学。她在坦桑尼亚莫希的乞力马扎罗山基督教医疗中心贡献了大量的时间来教学和指导住院医生。她还为住院医师开发了独特的教学技术，并创立了GlobalMedEd。Inc .是国际放射学培训的非营利组织。它的初始项目是GlobalRadZambia，其中包括赞比亚的第一个放射科住院医师，并利用一群由Wruble招募的美国顶级放射科医生的教学才能。为了减少过度治疗造成的伤害，改善医疗决策，鲁伯博士已经做出了努力。她已经就相关主题发表了两次TEDx演讲，一次是在宾夕法尼亚大学，另一次是在西点军校。在专业工作之余，鲁布尔喜欢与丈夫、五个成年子女和继子女共度时光。她是一个狂热的吉他手和耐力运动爱好者。她还致力于开发讲故事技巧，以提高医学生和住院医师的教育。
{"title":"January's reviewers of the month","authors":"","doi":"10.1111/bju.70103","DOIUrl":"https://doi.org/10.1111/bju.70103","url":null,"abstract":"<p>Like most journals, BJUI relies on the hard work and dedication of its peer reviewers and we are grateful to them all. Each month the Editorial Team nominates peer reviewers whose reviews have stood out for their quality and timeliness and those selected as the best are highlighted on this page in recognition of their exceptional work.</p><p>\u0000 <b>Tanja Hüsch</b>\u0000 </p><p>Her academic focus lies in functional and reconstructive urology, with expertise in neurourology, pelvic floor dysfunction, and urinary incontinence. She has led and contributed to several clinical studies on continence surgery and diagnostic innovation and received several honorary positions at national and international levels.</p><p>Dr. Hüsch's research has been supported by competitive scientific grants and acknowledged with national awards for applied clinical research. She has authored more than 70 peer-reviewed publications and contributed multiple textbook chapters to leading urology references.</p><p>As a Fellow of the European Board of Urology (FEBU), Dr. Tanja Hüsch serves as examiner and mentor, actively promoting academic advancement, education, and gender equity in urology.</p><p>\u0000 <b>Rustom Manecksha</b>\u0000 </p><p>He is a consultant urological surgeon with special interests in kidney stone disease and BPH and Clinical Associate Professor of surgery at Trinity College, Dublin. Prof. Manecksha is an active HST trainer and a former National Training Programme Director for Urology. He has an active research and academic profile with over 100 peer-reviewed publications.</p><p>\u0000 <b>Luis Ribeiro</b>\u0000 </p><p>\u0000 <b>Jill Wruble</b>\u0000 </p><p>Dr Wruble earned her undergraduate degree from Williams College and her medical degree from the New York Institute of Technology College of Osteopathic Medicine. She served in the United States Army Medical Corps, including a tour as a general medical officer at the 43rd MASH in Camp Humphreys, South Korea. She completed her internship and diagnostic radiology residency at Walter Reed Army Medical Center in Washington, D.C., followed by post-doctoral fellowships in body imaging at Georgetown University Medical School and Johns Hopkins Hospital in Baltimore. Dr Wruble retired from the Army with the rank of major. She was the recipient of an honorary doctorate and presented the medical school commencement address at the New York Institute of technology in 2025.</p><p>Dr Wruble serves on the National Cancer Institute's Board for Cancer Screening and Prevention, which critically evaluates medical literature and maintains evidence-based, up-to-date summaries on cancer screening and prevention for healthcare professionals and patients.</p><p>Dr Wruble has worked to enrich radiology teaching in underserved countries. She has contributed substantial time teaching and mentoring residents at Kilimanjaro Christian Medical Center in Moshi, Tanzania. She has also dev","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"137 1","pages":"8-9"},"PeriodicalIF":4.4,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1111/bju.70103","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145706280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：